Merck KGaA's Rebif, Teva's Copaxone similar-study
Oct 10 (Reuters) - Merck's Rebif multiple-sclerosis drug is not superior to rival Teva's Copaxone, a study obtained by Reuters on Wednesday showed.
"The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif," the report said.
The 96-week Phase IV study involving almost 800 patients will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague.
Merck inherited Rebif through its recent 10.2 billion-euro ($14 billion) acquisition of Swiss biotech company Serono. Serono had hoped to gain market share from Copaxone in the case of a positive outcome from the head-to-head study.
http://www.reuters.com/article/health-S ... 3420071010
dignan wrote:I wouldn't say this qualifies as big news, but if anybody is trying to make a choice right now...
Not surprisingly, the "big three" MS drug companies continue to spend millions of dollars on these head-to-head trials in the hope of "proving" their drug is better than the other guy's! A few percentage points of market share in this area translates into millions of dollars of additional revenue.
And yesterday I received a copy of MS Dialogue, a Canadian magazine about MS that is published 3 times a year. There was an article on page one that the Canadian Expert Drug Advisory Committee has recommended that Tysabri not be listed on Canadian drug formularies....translation....not to be covered by the government health drug plan. The main reason given was that the cost vs benefit equation compared to the existing approved MS drugs simply didn't warrant Tysabri being paid for by the government.
Oh, I almost forgot...this magazine and the associated website is heavily sponsored by Teva (the makers of Copaxone)!! The battles go on
If a trial or two showed that, watch how quickly these drug companies would change into attack mode and go after discrediting LDN!I'm really looking forward to the privately sponsored LDN trial. If that shows good results, the big three will be turned on their ears since LDN
is available in generic!
If they ever figure out about all of us hiding in the wings, watch out!! Who knows what meds they will dream up then.